A different approach to sexual health
Sexual health is a fundamental part of overall wellbeing, but it's also an area where people often struggle to get good medical guidance. Many treatments for sexual dysfunction focus on the mechanical aspects — blood flow, for example — without addressing the more complex issue of desire and arousal. For many people, especially those dealing with low libido or hypoactive sexual desire, the problem isn't about physical function. It's about wanting to in the first place.
Peptide therapy for sexual wellness offers a different approach. Rather than working on blood flow or hormones directly, certain peptides work on the brain's melanocortin system — the neural pathway that influences sexual desire and arousal at a central level. This makes them potentially useful for people whose sexual health concerns are rooted in desire rather than (or in addition to) physical function.
PT-141 / Bremelanotide
PT-141 (also known as Bremelanotide, brand name Vyleesi) is a melanocortin receptor agonist. It works by activating melanocortin 4 receptors (MC4R) in the brain, which are part of the neural circuitry involved in sexual arousal and desire. This mechanism is entirely different from PDE5 inhibitors like Viagra or Cialis, which work on blood flow.
The discovery of PT-141's sexual health effects was actually accidental. It was originally being studied as a tanning peptide (it's derived from the melanocortin system, which also regulates pigmentation). During clinical trials, researchers noticed a consistent and significant increase in sexual arousal among participants — leading to its development as a sexual health treatment.
How the melanocortin pathway works
The melanocortin system is a network of receptors and signaling molecules in the brain that regulates several basic functions including appetite, energy, pigmentation, and sexual behavior. The MC4 receptor, specifically, has been identified as playing a key role in the central processing of sexual signals.
When PT-141 activates MC4 receptors, it enhances the brain's response to sexual stimuli. It doesn't create arousal from nothing — it amplifies your brain's natural response to sexual cues. Think of it as turning up the volume on signals that are already there but have become too quiet to trigger a meaningful response.
This central mechanism means PT-141 can affect both desire (wanting) and arousal (physical readiness), which makes it fundamentally different from medications that only address the physical component.
FDA approval and clinical evidence
PT-141 was FDA-approved in 2019 under the brand name Vyleesi for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women. The approval was based on two Phase III clinical trials (RECONNECT studies) involving over 1,200 women. The results showed statistically significant increases in sexual desire and decreases in distress related to low sexual desire.
Regulatory status: PT-141 (Bremelanotide) is FDA-approved as Vyleesi for HSDD in premenopausal women. Its use in men and postmenopausal women is considered off-label. Off-label prescribing is legal and common in medicine when a physician determines it is clinically appropriate. Your physician will discuss the evidence base for your specific situation.
Use in women
For premenopausal women with HSDD — characterized by a persistent lack of sexual desire that causes personal distress — PT-141 represents the first FDA-approved treatment that works through the brain's desire pathways rather than through hormonal manipulation.
In clinical trials, women using PT-141 reported increased sexual desire, greater satisfaction with sexual experiences, and reduced distress about their low libido. It's administered as a subcutaneous injection approximately 45 minutes before anticipated sexual activity — not taken daily like some other sexual health medications.
It's important to set realistic expectations. PT-141 works for some women but not all. In clinical trials, approximately 25% of women showed meaningful improvement compared to 17% with placebo. The effect is real but not universal. Your physician can help you determine if it's worth trying based on your specific situation.
Use in men
While PT-141 is not FDA-approved for use in men, there is clinical evidence supporting its efficacy. Several clinical studies have shown that PT-141 can improve erectile function in men, including some who did not respond to PDE5 inhibitors (Viagra, Cialis). This makes biological sense — if erectile dysfunction has a significant central/desire component, a medication that works on the brain may help where blood flow medications don't.
PT-141 may be particularly relevant for men whose sexual health concerns include reduced desire or arousal in addition to (or instead of) erectile difficulty. It can also be used in combination with PDE5 inhibitors, addressing both the central and peripheral components of sexual function.
Off-label use in men is based on clinical evidence and physician judgment. Your Meridian physician will discuss the evidence, set realistic expectations, and determine if PT-141 is an appropriate option for your situation.
What it does and doesn't do
What PT-141 does:
- Activates the brain's melanocortin pathway to enhance sexual desire and arousal
- Works on a "when needed" basis — administered before anticipated sexual activity
- Can help with both desire (wanting) and arousal (physical readiness)
- Offers an alternative mechanism for people who haven't responded to other treatments
What PT-141 doesn't do:
- It doesn't create desire out of nothing — it enhances your response to sexual cues
- It doesn't fix relationship issues, psychological barriers, or other non-biological factors
- It's not a hormone — it doesn't change your testosterone, estrogen, or other hormone levels
- It doesn't work for everyone — individual responses vary
Side effects
The most common side effect is nausea, which affects approximately 40% of patients. It's typically mild and transient, lasting 1–2 hours after injection. Some patients experience flushing, headache, or temporary changes in blood pressure. A small percentage of patients develop transient darkening of the gums or skin at the injection site due to the melanocortin system's role in pigmentation. This is reversible.
PT-141 should not be used more than once in a 24-hour period, and no more than 8 times per month. It is not recommended for patients with uncontrolled hypertension or significant cardiovascular disease.
Frequently asked questions
How is PT-141 different from Viagra or Cialis?
They work through completely different mechanisms. Viagra and Cialis are PDE5 inhibitors that increase blood flow to the genitals — they help with the physical mechanics of erection but don't affect desire. PT-141 works in the brain on the melanocortin pathway that governs sexual desire and arousal. It can help with the "wanting" part of sexual response, which PDE5 inhibitors don't address. For some patients, combining both approaches may be more effective than either alone.
How quickly does PT-141 work?
PT-141 is typically administered 45 minutes to an hour before anticipated sexual activity. Effects generally begin within 30–60 minutes and can last for several hours. Unlike daily medications, it's used on an as-needed basis, which gives patients more control over timing.
Is it safe to use PT-141 with other medications?
PT-141 can potentially interact with blood pressure medications, so your physician will review your complete medication list before prescribing. It should be used with caution alongside other melanocortin-active drugs. It does not have significant interactions with PDE5 inhibitors, so combination use is generally considered safe under physician guidance.
Is this just for people with diagnosed sexual dysfunction?
Clinically, PT-141 is indicated for hypoactive sexual desire disorder — a persistent, bothersome lack of sexual desire. However, the line between "normal" age-related changes and clinical dysfunction can be blurry. If reduced sexual desire is affecting your quality of life or your relationship, it's worth discussing with a physician regardless of whether it meets a specific diagnostic threshold. Your physician will evaluate your situation holistically.
Ready to address sexual wellness?
Request PT-141 (Bremelanotide) during your assessment. It's FDA-approved and available through our physician network.